Abstract
Platinum-based combinations constitute the backbone of chemotherapy in NSCLC. Furthermore, the regimens resulting from the addition of immunotherapy are considered the state of the art in treating advanced disease. Different platinum analogues are considered to exhibit similar activity; however, toxicity may differ. In an effort to identify these differences, we collected NSCLC patients’ reported data on side-effects.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
